Author: Ramona Adams|| Date Published: September 14, 2016
Mylan Pharmaceuticals (Nasdaq: MYL) has won a potential $121.5 million contract from the Defense Logistics Agency to provide lidocaine 5 percent patch, a medicine designed for the treatment of post-herpetic neuralgia pain.
Mylan will supply the medical product to the departments of Defense and Veterans Affairs as well as the Indian Health Services and Federal Bureau of Prisons under the firm-fixed-price contract, DoD said Tuesday.
DoD noted the contract has one base year and four option years.
The company will perform work in West Virginia, Vermont and North Carolina through Sept. 12, 2021.
DLA Troop Support received four proposals for the contract and will obligate defense working capital funds in fiscal year 2017 through fiscal 2021.
XLA, a provider of cybersecurity, data management and analytics, technical services, and international program support, has appointed James Vant as chief…
Understanding how organizations can prepare for a Cybersecurity Maturity Model Certification, or CMMC, assessment often starts with structured road maps…
The Department of Transportation is undergoing rapid transformation under Transportation Secretary Sean Duffy. Since stepping into the role in January 2025, Duffy…
Mylan Pharmaceuticals (Nasdaq: MYL) has won a potential $121.5 million contract from the Defense Logistics Agency to provide lidocaine 5 percent patch, a medicine designed for the treatment of post-herpetic neuralgia pain.
